Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Addex Therapeutics : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

09/08/2021 | 01:00am EDT

Geneva, Switzerland, September 8, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 - 15, 2021).

In his presentation, which is scheduled for Monday, September 13, 2021 at 07:00 ET / 13:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing on-demand by registered participants via this link from the time of the presentation and subsequently on the Events page the Company’s website (www.addextherapeutics.com). The video replay will be archived for 90 days following the event.

Management will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.


Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55        
Mike Sinclair
Partner, Halsin Partners
+44 (0)20 7318 2955
James Carbonara
Hayden IR

Forward Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.


Primary Logo

Source: Addex Therapeutics

2021 GlobeNewswire, Inc., source Press Releases

10/06PRESS RELEASE : Addex to Present at the Investors' Day hosted by Voxia Communication
10/06ADDEX THERAPEUTICS : to Present at the Investors' Day hosted by Voxia Communication
10/06ADDEX THERAPEUTICS : Addex to Present at the Investors' Day hosted by Voxia Communication
10/06Addex to Present at the Investors' Day hosted by Voxia Communication
10/04PRESS RELEASE : Addex to Present at the 10th -2-
10/04PRESS RELEASE : Addex to Present at the 10th International Meeting on Metabotropic Glutama..
10/04Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
09/29ADDEX THERAPEUTICS : Type of dystonia characterized by involuntary spasms of the eyelid mu..
09/29ADDEX THERAPEUTICS : Commences Mid-Stage Trial of Dipraglurant in Blepharospasm
09/29ADDEX THERAPEUTICS : Starts Mid-Stage Trial For Eyelid Muscles Spasm Drug
More news
Analyst Recommendations on ADDEX THERAPEUTICS LTD
More recommendations
Sales 2021 2,35 M 2,57 M 2,57 M
Net income 2021 -16,5 M -18,0 M -18,0 M
Net Debt 2021 5,28 M 5,76 M 5,76 M
P/E ratio 2021 -2,60x
Yield 2021 -
Capitalization 42,6 M 46,5 M 46,5 M
EV / Sales 2021 20,4x
EV / Sales 2022 35,6x
Nbr of Employees 27
Free-Float 65,1%
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,25 CHF
Average target price 25,72 CHF
Spread / Average Target 1 958%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233